NEWS

Vaccine Hesitancy Foundations: A Fact-Based Offering to Encourage Vaccination and Fight COVID-19

WASHINGTON (May 7, 2021) – AM TRACE LLC, a public health firm that supports state and local health departments to mitigate the spread of COVID-19 in their communities, has consulted data analysts and public health professionals to compile an unbiased brief to better inform patients on the benefits of receiving the COVID-19 vaccine.

Across the Nation debate carries on regarding the efficacy, and even safety, of receiving the vaccine designed to build immunity against the novel-coronavirus, SARS CoV-2. As we anxiously await the coveted designation of herd-immunity, we need to be informed of the evolution of the virus as many choose to play a waiting game – which is playing out on a global scale as a dangerous game.

In the largest global undertaking in the history of modern medicine, we now see the results as a variety of vaccines available that have been studied by the Food and Drug Administration, and licensed for use under an Emergency Use Authorization, or EUA.

“While some are reluctant to receive their vaccination, we have to be aware of what is happening around us. A virus has an opportunity to evolve within each host that carries it. Put simply, the fewer susceptible individuals in the world, the more likely we are to curtail the number of newly emerging variants, and get the pandemic under a level of control”, stated Dan Gabriel, CEO AM TRACE LLC. He continued, “it is the mission of AM TRACE to continue partnering with State and Local governments to continue broad testing, contact tracing, and vaccination efforts – because we know it’s working.”. 

 

AM TRACE is currently working nationwide with multiple states and public health agencies on testing, tracing, and vaccination programs. Counties or states that are interested in partnering with AM TRACE for COVID-19 mitigation support, including marketing support to formulate messaging and campaigns surrounding Vaccine Hesitancy, should connect with AM TRACE, via Dr. Christopher K Orlea at c.orlea@am-trace.co

Related NEWS